Kisaco Pharma & Biotech Patent Litigation Summit 2026

Fish & Richardson Principals Gwilym Attwell, Rae Crisler, and Jonathan Singer will speak at the Kisaco Pharma & Biotech Patent Litigation Summit in Amsterdam on January 19 and 20, 2026.

Fish is proud to support the Pharma & Biotech Patent Litigation Summit, which gathers pharmaceutical and biotech leaders for critical conversations on the legal strategies, regulatory updates, and innovations shaping the future of IP protection in the life sciences. Session details are below.

Multi-Jurisdictional Biologics and Biosimilar Litigators Review: The UPC, UK, Türkiye, Canada, and the USA | Gwilym Attwell

This session provides an in-depth analysis of recent high-profile biologics and biosimilar patent disputes across Europe, the USA, and Asia, including landmark cases involving Xtandi, Soliris, and antibody exclusivity challenges. Attendees will explore how evolving case law, patent claim constructions, and regulatory developments are shaping exclusivity periods, enforcement strategies, and market entry pathways. The session will also address comparative litigation trends, strategic patent considerations, and the complexities of navigating both branded and biosimilar patent conflicts globally.

Roundtable Discussion: Hatch-Waxman Litigation Review in the USA | Rae Crisler

The Development of the Doctrine of Equivalents Case Law: Comparing the UPC With National Jurisdictions | Jonathan Singer

This session examines how the UPC’s evolving case law on equivalence compares with national practices in jurisdictions such as the UK, Germany, and Brazil. With recent UPC decisions applying the four-prong test to life sciences disputes, panelists will assess whether the doctrine is delivering legal certainty while ensuring fair protection for patentees.

For more information, or to register, click here.